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Mutations in the Plasmodium 
falciparum chloroquine resistance 
transporter, PfCRT, enlarge the 
parasite’s food vacuole and alter 
drug sensitivities
Serena Pulcini1,*, Henry M. Staines1,*, Andrew H. Lee2, Sarah H. Shafik3,  
Guillaume Bouyer1,4,5, Catherine M. Moore1, Daniel A. Daley6, Matthew J. Hoke6, 
Lindsey M. Altenhofen7, Heather J. Painter7, Jianbing Mu8, David J. P. Ferguson9, 
Manuel Llinás7, Rowena E. Martin3, David A. Fidock2,10, Roland A. Cooper6,11 & Sanjeev Krishna1
Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, are the major 
determinant of chloroquine resistance in this lethal human malaria parasite. Here, we describe  
P. falciparum lines subjected to selection by amantadine or blasticidin that carry PfCRT mutations 
(C101F or L272F), causing the development of enlarged food vacuoles. These parasites also have 
increased sensitivity to chloroquine and some other quinoline antimalarials, but exhibit no or 
minimal change in sensitivity to artemisinins, when compared with parental strains. A transgenic 
parasite line expressing the L272F variant of PfCRT confirmed this increased chloroquine sensitivity 
and enlarged food vacuole phenotype. Furthermore, the introduction of the C101F or L272F mutation 
into a chloroquine-resistant variant of PfCRT reduced the ability of this protein to transport 
chloroquine by approximately 93 and 82%, respectively, when expressed in Xenopus oocytes. These 
data provide, at least in part, a mechanistic explanation for the increased sensitivity of the mutant 
parasite lines to chloroquine. Taken together, these findings provide new insights into PfCRT function 
and PfCRT-mediated drug resistance, as well as the food vacuole, which is an important target of 
many antimalarial drugs.
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Chloroquine (CQ) rapidly became one of the most useful antimalarial drugs for first-line therapy soon 
after the Second World War. Resistance to CQ was first reported in the late 1950s in Plasmodium fal-
ciparum. It then spread globally and forced the development of alternative regimes, culminating in the 
more expensive artemisinin-based combination therapies (ACTs) used today. The locus containing the 
P. falciparum chloroquine resistance transporter gene (pfcrt) was initially mapped by classical genetic 
studies as being crucial to the development of CQ resistance, with this gene subsequently being identified 
and its role confirmed using reverse genetic approaches1–3. CQ resistance is now emerging in P. vivax, 
for which it remains the first-line treatment4.
CQ is a diprotic weak base that accumulates in the parasite’s acidic food vacuole (FV) by diffusion 
and subsequent trapping by protonation. CQ interferes with the detoxification of heme in the FV, which 
leads to parasite death5. Predicted to have 10 transmembrane domains (TMDs), PfCRT is located in the 
FV membrane1,6 and, when mutated, increases export of CQ from the FV and its target of heme polym-
erisation7. Single nucleotide polymorphisms (SNPs) in PfCRT in field isolates correlate with a resistance 
phenotype in in vitro assays and are sensitive markers for treatment failure in patients8,9. However, these 
molecular markers are not always specific because other variables such as previous exposure to malaria 
can influence treatment response in patients10.
One polymorphism at position 76 (K76T) in the first TMD of PfCRT seems to be key to CQ resist-
ance. This substitution removes a positive charge from a predicted substrate-binding site in PfCRT, allow-
ing protonated CQ to escape from the FV down its electrochemical gradient11. Other mutations (K76I 
and K76N) in this position also arise when P. falciparum is exposed in vitro to lethal concentrations of 
CQ, allowing parasites to survive and supporting the critical role of this residue1,6.
The native function of PfCRT is not clear, although it has been postulated to be involved in hemoglo-
bin catabolism, possibly by mediating the transport of hemoglobin-derived peptides/amino acids from 
the FV12, a hypothesis consistent with recent heterologous expression and metabolomics studies7,13,14. 
PfCRT has also been proposed to function as a chloride channel, a proton pump or a regulator of 
proton pumps, a general activator or modulator of transport systems (reviewed in11) or, most recently, 
a proton-coupled transporter of a broad range of cationic substrates15. There are many reasons to eluci-
date the function of PfCRT in parasites, including the suggestion that PfCRT could itself become a new 
drug target16,17, or that chemosensitizing agents could be directed against PfCRT to restore the efficacy 
of CQ16–18. Furthermore, CQ continues to be used in the treatment of non-falciparum malarias. It may 
also regain efficacy against falciparum malaria in areas where usage has been tightly regulated, since the 
withdrawal of CQ can result in dramatic decreases in the prevalence of CQ-resistant parasites19.
Here, mutations in pfcrt that alter parasite phenotype give new insights into its native function as a 
transporter. The novel and pleiotropic phenotypic characteristics associated with mutated PfCRT include 
altered FV morphology and changes in quinoline sensitivities. We also investigated the effect of these 
changes on the parasite’s sensitivity to other antimalarial classes, such as the artemisinins, that some have 
considered to act (at least in part) in the FV of the parasite20,21.
Results
New and previously described mutations in pfcrt. SNPs were identified in pfcrt in two different P. 
falciparum lines (Fig. 1a,b). The first was discovered after isolating amantadine (AMT)-resistant mutants 
of the CQ-resistant parasite strain FCB, following selection with 80 μ M of this antiviral agent. Viable par-
asites were observed in one of four drug-pressured flasks at 42 days, whereas none had emerged within 
the remaining flasks by 60 days. PCR amplification and sequencing of pfcrt in four clonal lines derived 
from the AMT-resistant culture detected a single non-synonymous SNP, g302t. This encoded the amino 
acid mutation C101F. These lines were therefore designated FCBC101F. Position 101 is predicted to lie 
within the second TMD of PfCRT (Fig. 1a). This mutation was earlier observed in a CQ-resistant Dd2 
parasite line derived by continuous piperaquine (PPQ) pressure22, although that study did not describe 
any changes in parasite morphology.
The second parasite line, derived from the CQ-sensitive strain 3D7, was selected by blasticidin (BSD) 
pressure as an inadvertent outcome of transfection experiments on an unrelated gene (that had aimed 
to achieve single cross-over homologous recombination with a tagging plasmid under BSD selection)23. 
After several weeks of selection, pfcrt cDNA transcripts of the daughter parasite line and parental 3D7 
were sequenced. A mutation at position c814t in the pfcrt coding sequence, resulting in the amino acid 
mutation L272F, was detected in the selected line, designated 3D7L272F, and was absent in its parent. This 
substitution is positioned immediately after the seventh predicted TMD, placing it in the FV compart-
ment (Fig. 1a). To our knowledge, this mutation has not been reported previously. No other mutations 
in pfcrt were detected in either of the new parasite lines.
Given that 3D7L272F arose in unusual circumstances (BSD is a general inhibitor of protein translation 
and is not thought to target the FV), whole-genome sequencing was undertaken to identify further 
mutations. This confirmed the presence of the c814t mutation in pfcrt and identified only 2 additional 
SNPs. The first was c5549g in PF3D7_1229100 (the P. falciparum multidrug resistance-associated pro-
tein 2, PfMRP2), resulting in a stop-gain mutation (S1850*) and the loss of 259 amino acids from the 
C-terminus. The second was t1032a in PF3D7_1462400 (a conserved protein of unknown function), 
resulting in a stop-gain mutation (Y344*) and the loss of 2979 amino acids from the C-terminus. 
Truncation of the latter sequence has been observed in other laboratory clones of 3D724. Furthermore, 
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there was no evidence of integrated copies of the plasmid vector containing the BSD selection marker23, 
which had been used during the generation of the 3D7L272F line.
Enlarged FVs of parasites with mutations in pfcrt. A monstrously swollen FV was observed at all 
stages that ordinarily display a vacuole in the asexual cycle of both parasite lines FCBC101F and 3D7L272F 
(Fig. 2). This phenotype was stably maintained in the parasites following repeated rounds of parasite cul-
ture and cryopreservation. The enlarged FVs were already apparent in the early to mid trophozoite stages 
of the FCBC101F line, when compared with FVs from FCB parental controls (Fig. 2a left and right panels). 
In more mature FCBC101F parasites, the FVs were strikingly clear in appearance, with hemozoin crystals 
apparently marginalized to the FV periphery and opposite the developing nuclei, although live imaging 
suggests that the hemozoin is distributed normally (Fig. 2b). The immature ring stages of development 
were indistinguishable from those of the parental strain. Similar findings were evident in the parasite 
line 3D7L272F when compared with 3D7 (Fig. 2c left and right panels). Measurement of the area of the 
FV was also undertaken and expressed as a ratio of the parasite’s area to correct for parasite age (Fig. 3a). 
This confirmed that FCBC101F and 3D7L272F parasites have a relative FV/parasite area that is approximately 
twice that of FCB and 3D7, respectively (p < 0.0001). Neither FCBC101F nor 3D7L272F parasites appeared 
to be enlarged within their host red blood cells (RBCs).
The 3D7L272F line was selected for a more detailed characterization. The appearances of parasites 
examined with transmission electron microscopy (TEM) were consistent with observations made with 
light microscopy (Fig. 3b,c), with few differences evident between parental strains and daughter parasite 
lines except for the size of the FV. Specific to this line, TEM also revealed that “knobs”, electron dense 
protrusions of the RBC membrane caused by parasite infection, which are important determinants of 
cytoadherence25 and which are often lost from infected RBCs during long term parasite culture26, were 
Figure 1. PfCRT mutations. (a) Schematic representation of PfCRT and positions of previously identified 
polymorphisms8,71 from field isolates (green circles) and from drug-pressured laboratory lines (purple 
circles). The critical CQ resistance mutation site (K76) is shaded red, and the two residues at which 
mutations are described in this study are shaded in orange (C101) and blue (L272). (b) PfCRT haplotypes 
included this study.
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displayed approximately 7.5-fold more on the host surface of 3D7L272F-infected RBCs than 3D7-infected 
RBCs. This is unlikely to be directly related to the mutation in pfcrt and may be due to sub-population 
selection.
Since BSD pressure has been shown to alter infected RBC permeability27–29, electrophysiological 
transport studies were also undertaken to compare 3D7 and 3D7L272F-infected RBCs, although no differ-
ences were observed (Supplementary Fig. S1).
Figure 2. Representative morphology of parasite lines FCBC101F and 3D7L272F. (a) Appearance of 
enlarged FVs in fixed FCBC101F parasites (left panel), when compared with parental FCB parasites of similar 
developmental stages (right panel). (b) Images of live FCBC101F and FCB trophozoite-stage parasites, using 
bright-field and dark-field microscopy (left and right panels, respectively). (c) Appearance of enlarged FVs 
in fixed 3D7L272F parasites (left panel), when compared with parental 3D7 parasites of similar developmental 
stages (right panel). The diameter of a RBC is ~7 μ m.
www.nature.com/scientificreports/
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In vitro sensitivity to antimalarials. Both cell lines with mutations in pfcrt displayed altered suscep-
tibility to antimalarials when compared with the parental strains (Table 1). Using a 72 h in vitro growth 
inhibition assay that yields IC50 values, FCBC101F parasites were found to be 83 fold less susceptible to 
AMT (used in its selection). FCBC101F showed a 5–6 fold increase in sensitivity to CQ, yet interestingly 
still retained the characteristic verapamil (VP)-reversibility of CQ-resistant parasites30. Furthermore, 
compared with FCB, FCBC101F was significantly (p < 0.01) more sensitive to quinolines (quinine (QN), 
quinidine (QD) and monodesethyl amodiaquine (MDAQ)) but not the arylmethanol, mefloquine (MQ). 
There was a small (29%) increase in sensitivity to artemisinin (ART; p <0.01). The FCBC101F line became 
approximately 2-fold more resistant to PPQ relative to controls (p < 0.05).
In similar experiments, 3D7L272F parasites, assayed over 48 h in vitro, were ~2.5 fold more sensitive to 
CQ than 3D7, with respective IC50 values of 6.1 and 15 nM (p < 0.01). The 3D7L272F parasites were also 
slightly more sensitive to QN than 3D7 parasites. VP sensitivity was not examined because unlike FCB, 
the 3D7 line is already CQ-sensitive. The increased sensitivity to CQ therefore indicates that 3D7L272F is 
Figure 3. Morphological comparisons of parasites with mutations in pfcrt compared with their parental 
controls. (a) Parasites were synchronized by sorbitol lysis and areas of FVs and parasites (approximately 
38 h post-invasion) were measured and expressed as ratios (AFV/AParasite). 3D7, FCB and Dd2Dd2 (open 
bars; n = 72, 31 and 42, respectively) and 3D7L272F, FCBC101F and Dd2Dd2 L272F (closed bars; n = 84, 58 and 
88, respectively) parasites were analyzed and significant enlargement of the FV was confirmed in 3D7L272F, 
FCBC101F and Dd2Dd2 L272F parasites relative to 3D7, FCB and Dd2Dd2, respectively (*p < 0.0001: two-
tailed, unpaired, Student’s t-test). (b,c) Transmission electron micrographs of 3D7 and 3D7L272F parasites, 
respectively, showing the food vacuole (FV) and nucleus (N). Note the enlarged electron lucent FV in 
3D7L272F (suggesting changes in the process of hemoglobin degradation and formation of hemozoin crystals). 
RBCs infected with 3D7L272F displayed approximately 7.5-fold more knobs (arrowheads) on the host surface 
than 3D7-infected RBCs, although this is likely due to sub-population selection rather than a direct link to 
the mutation in pfcrt. (insert) Detail of a knob. Bars represent 1 μ m (b,c) and 100 nm (insert).
Drug†
Mean ± SEM IC50 values for individual parasite strains/lines‡
3D7 3D7L272F FCB FCBC101F FCB + VP FCBC101F + VP
CQ 15 ± 1.8 6.1 ± 1.5* 187 ± 7.1 34 ± 1.8* 47 ± 1.2 14 ± 1.0
QN 176 ± 17 108 ± 13* 333 ± 5.8 220 ± 23* 161 ± 33 223 ± 31
QD — — 167 ± 13 62 ± 3.1* 46 ± 1.9 46 ± 2.9
MQ 87 ± 29 64 ± 17 13 ± 1.1 14 ± 0.9 8.8 ± 1.0 18 ± 2.0
AQ 25 ± 2.3 27 ± 2.1 — — — —
MDAQ 14 ± 1.5 15 ± 1.5 52 ± 4.1 18 ± 1.0* 16 ± 1.0 9.1 ± 0.7
PPQ 18 ± 4.1 22 ± 5.3 12 ± 0.6 27 ± 1.8* 13 ± 0.4 25 ± 3.1
ART 3.5 ± 1.2 4.1 ± 1.6 13 ± 0.9 9.1 ± 0.7** 9.9 ± 0.9 9.1 ± 0.5
BSD (μ M) 1.5 ± 0.6 47 ± 6.0* — — — —
AMT (μ M) — — 5.6 ± 0.6 465 ± 54* 11 ± 0.5 687 ± 32
Table 1.  In vitro sensitivity of 3D7, 3D7L272F, FCB and FCBC101F (in presence or absence of verapamil, 
VP) to antimalarial drugs. †CQ, chloroquine; QN, quinine; QD, quinidine; MQ, mefloquine; AQ, 
amodiaquine; MDAQ, monodesethyl amodiaquine; PPQ, piperaquine; ART, artemisinin; BSD, blasticidin; 
AMT, amantadine; VP, verapamil (used at 0.8 μ M). ‡IC50 values are listed in nM, except where indicated, 
and are show as the mean ± SEM. n = 3 independent assays (each performed as a single replicate for FCB 
parasites and in quintuplicate for 3D7 parasites). Significantly different mean IC50 values relative to controls 
(F-test; *p < 0.05, **p < 0.01).
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a ‘CQ-hypersensitive’ parasite line. The mean IC50 values for MQ, MDAQ, PPQ and ART were similar 
between the 3D7L272F and 3D7 parasites (Table 1).
Transfection studies. To confirm the phenotype observed in 3D7L272F, we engineered the L272F 
mutation in pfcrt using zinc-finger nuclease mediated allelic replacement31 in the Dd2 line and compared 
results with congenic controls. Figure  4a,b illustrate this strategy and provide confirmation of integra-
tion. As observed in 3D7L272F, significant FV distension (~2 fold as measured by vacuolar area relative 
to parasite area; Fig.  3a) was generated by introduction of this single amino acid change (Fig.  4c,d). 
However, a significant increase in BSD resistance was not observed between the Dd2Dd2 L272F line and its 
congenic control, Dd2Dd2 (Table  2), which suggests that the PfCRT L272F mutation was not primarily 
responsible for the BSD resistance found in 3D7L272F parasites. The parental strain Dd2 and the congenic 
control Dd2Dd2 were both CQ-resistant. However, Dd2Dd2 L272F was considerably more susceptible to CQ 
and monodesethyl chloroquine (MDCQ) than the Dd2Dd2 line, although the IC50 values of the L272F 
Figure 4. Introduction of PfCRT L272F into Dd2. (a) Schematic of zinc-finger nuclease (ZFN)-mediated 
generation of vacuole-enlarged parasites. Dd2 parasites were first enriched for the episomal pcrtDd2 L272F-
hdhfr or pcrtDd2-hdhfr donor plasmids (latter not shown). The donor plasmids encoded a cDNA copy of 
the Dd2 pfcrt allele (dark blue, plasmid), either L272F-mutated (dark blue bump) or wild-type (not shown), 
followed by a dhfr selection cassette (light grey). Each donor-enriched parasite was then transfected with 
the pZFNpfcrt-bsd plasmid, expressing the genomic (light blue) pfcrt intron 1-targeting ZFN pair (ZFN L 
and ZFN R, orange) and the bsd selection cassette (dark grey). ZFN-induced recombination in pfcrt yielded 
either control Dd2Dd2 (not shown) or Dd2Dd2 L272F parasites (dark blue, locus). (b) PCR verification of 
parental, recombinant control, and Dd2Dd2 L272F parasite clones. Primer (p) positions are shown in panel a. 
(c) Light microscope analysis of representative examples of parental, recombinant control, and experimental 
parasite clones. Ring morphology for each parasite Dd2, Dd2Dd2, Dd2Dd2 L272F, and GC03 was normal. 
Progression through the trophozoite and schizont stages showed normal morphological development 
except for the Dd2Dd2 L272F clone, which exhibited the characteristic enlarged vacuole and diffuse hemozoin 
phenotypes seen in 3D7L272F and FCBC101F Giemsa stained parasites. (d) Transmission electron micrographs 
of Dd2Dd2 (i) and Dd2Dd2 L272F parasites (ii) showing similar cytoplasmic appearances except for the enlarged 
food vacuole (FV) in Dd2Dd2 L272F. Note neither parasite exhibits knobs. This confirms similar morphological 
appearances to those of 3D7 and 3D7L272F, respectively but without knob formation. N—Nucleus. Bars 
represent 1 μ m.
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mutant remained higher than the fully CQ-sensitive reference line GC03 (Table 2). ART sensitivity, as 
measured in these IC50 assays, was unaltered across parasites. There were no differences in whole-cell 
electrophysiological properties between the Dd2Dd2 and Dd2Dd2 L272F parasite lines (Supplementary Fig. 
S1) and the RBCs infected with Dd2Dd2 L272F parasites remained knobless (Fig.  4d), suggesting that the 
increased expression of knobs in 3D7L272F-infected RBCs was not related to the L272F mutation in pfcrt.
Measurements of CQ transport via the C101F and L272F variants of PfCRT. The Xenopus 
oocyte system for the heterologous expression of PfCRT7 was employed to investigate the effect of the 
C101F and L272F mutations on the ability of PfCRT to mediate CQ transport. The L272F and C101F 
mutations were introduced into the Dd2 haplotype of PfCRT (PfCRTDd2, from the CQ-resistant strain 
Dd2; Fig. 1b) and L272F was also introduced into PfCRT3D7 (from the CQ-sensitive strain 3D7; Fig. 1b). 
The resulting variants (L272F PfCRTDd2, L272F PfCRT3D7, and C101F PfCRTDd2), as well as PfCRTDd2 and 
PfCRT3D7, were expressed in oocytes. Localization of each of the PfCRT variants to the oocyte plasma 
membrane was confirmed by immunofluorescence assay (Supplementary Fig. S2a) and a semiquantita-
tive western blot analysis32 indicated that the different PfCRT proteins were present at similar levels in 
the oocyte membrane (Supplementary Fig. S2b). The ability of the PfCRT variants to mediate [3H]CQ 
transport was measured in an acidic medium (pH 5.5), in which the majority of CQ is protonated. The 
extent to which oocytes expressing PfCRTDd2 accumulate [3H]CQ varies considerably between batches 
of oocytes from different frogs, with the PfCRTDd2-expressing oocytes accumulating between 8 and 45 
times more [3H]CQ than the control (non-injected and PfCRT3D7-expressing) oocytes. Hence, within 
each experiment uptake was expressed relative to that obtained for oocytes expressing PfCRTDd2 (in 
the absence of inhibitors). Non-injected oocytes and oocytes expressing PfCRT3D7 have previously been 
shown to take up CQ to similar (low) levels via simple diffusion of the neutral species of the drug7,32; 
this represents the ‘background’ level of CQ accumulation in oocytes, which in this study was estimated 
by measuring CQ uptake into PfCRT3D7-expressing oocytes (see Supplementary Fig. S3).
In the data presented in Fig. 5a,b, oocytes expressing PfCRTDd2 showed an 11 to 40-fold (mean and 
SEM of 21 ± 3; n = 9 separate experiments) increase in CQ uptake relative to the PfCRT3D7-expressing 
control. The component of CQ accumulation attributable to diffusion (i.e. the uptake of CQ measured 
in PfCRT3D7-expressing oocytes) was subtracted to obtain the PfCRT-mediated component of CQ trans-
port. Supplementary Figure S3 shows the total level of CQ accumulation in each oocyte and treatment 
type. The introduction of L272F or C101F into PfCRTDd2 substantially reduced the protein’s ability to 
transport CQ (by ~82% and ~93%, respectively; p < 0.001, ANOVA) whereas the introduction of L272F 
into PfCRT3D7 was without effect (p > 0.05). The addition of the CQ resistance-reverser VP (250 μ M) 
reduced PfCRTDd2-mediated CQ transport by ~93% (p < 0.001) and also dramatically decreased CQ 
uptake via L272F PfCRTDd2 and C101F PfCRTDd2 (by ~84% and ~92%, respectively; p < 0.01), such that 
the accumulation of CQ in the latter two treatments was not significantly different from that measured 
in the PfCRT3D7-expressing controls (p > 0.05).
To investigate how BSD pressure might have produced the 3D7L272F mutant, interactions between 
the PfCRT variants and BSD were assessed by measuring the uptake of [3H]CQ in the presence of 
unlabeled BSD (100 or 500 μ M; Fig.  5b). The addition of BSD reduced CQ transport via PfCRTDd2 by 
~39% (100 μ M; p < 0.001) and ~56% (500 μ M; p < 0.001) and, to a lesser degree, decreased CQ uptake 
via L272F PfCRTDd2 (by ~22% (p > 0.05) and ~49% (p < 0.01), respectively). Neither concentration of 
BSD reduced the C101F PfCRTDd2-mediated transport of CQ (p > 0.05), nor was the accumulation of 
CQ in the PfCRT3D7-expressing controls affected (p > 0.05). Note that the micromolar concentrations of 
the compounds used here to inhibit PfCRT are physiologically relevant given that when present in the 
Drug†
Mean ± SEM IC50 values for individual parasite strains/lines‡
Dd2 Dd2Dd2 Dd2Dd2 L272F GC03
CQ 97 ± 6.8 88 ± 6.8 20 ± 1.8* 13 ± 2.3
MDCQ 497 ± 43 440 ± 33 121 ± 9.0* 26 ± 3.0
MDAQ 45 ± 5.8 35 ± 3.6 22 ± 4.0** 18 ± 1.1
PPQ 32 ± 3.1 32 ± 5.8 39 ± 1.5 23 ± 5.3
ART 18 ± 1.1 18 ± 4.6 13 ± 1.9 15 ± 4.7
BSD 456 ± 46 631 ± 35*** 708 ± 54 456 ± 59
Table 2.  In vitro sensitivity of Dd2, Dd2Dd2, Dd2Dd2 L272F and GC03 to antimalarial drugs. †CQ, 
chloroquine; MDCQ, monodesethyl chloroquine; MDAQ, monodesethyl amodiaquine; PPQ, piperaquine; 
ART, artemisinin; BSD, blasticidin. ‡IC50 values are listed in nM and are shown as the mean ± SEM. n = 3 
independent assays (each performed in duplicate). Significantly different mean IC50 values between Dd2Dd2 
and Dd2Dd2 L272F (F-test; *p < 0.0001, **p = 0.07) and between Dd2 and Dd2Dd2 (F-test; ***p = 0.038).
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extracellular solution at nanomolar levels, these protonatable drugs are expected to accumulate within 
the parasite’s FV via weak-base trapping to micromolar or millimolar concentrations.
Discussion
Mannaberg stained parasites with Romanowsky’s dyes and published detailed studies on the effects of 
QN against P. falciparum, which described the emergence of a ‘dropsical distension’ (enlarged FV) in 
mature parasites33. Here, we describe a similar peculiar phenotype of P. falciparum parasites that is visible 
without the application of antimalarial drugs. This phenotype is comparable between two parasite lines 
that have mutations in pfcrt in different positions (amino acids 101 and 272) and that have been selected 
by two chemically unrelated compounds (AMT and BSD). These mutations confirm that pfcrt encodes a 
function that is critical to maintaining FV volume. In support of this function, mutations in PfCRT that 
cause CQ resistance have been reported to increase FV volume34. However, the parasite lines described 
in this present study have clearly enlarged FVs but with PfCRT mutations that render the parasites more 
CQ sensitive than their control strains (be that either CQ-sensitive 3D7 or CQ-resistant FCB), suggesting 
an alternative mechanism of FV volume regulation is induced.
An enlarged FV is also often observed in the presence of protease inhibitors, such as E64 or leupep-
tin35. Interference with the digestion of hemoglobin leads to a buildup of darkly staining FVs in electron 
micrographs and, eventually, to parasite death. The parasites described here have enlarged FVs but these 
are electron lucent (Figs  2 and 4), suggesting that the digestion of hemoglobin is relatively unaffected 
(further supported by the presence of visible hemozin within the FVs). The simplest explanation for these 
observations is that the C101F and L272F mutations interfere with the transport of the natural substrates 
of PfCRT out of the FV. The resulting increase in FV osmotic pressure would lead to water ingress and 
produce the unusual swelling observed in the FV of the FCBC101F, 3D7L272F, and Dd2Dd2 L272F parasites. 
Figure  6 presents a schematic model of this process. These morphological changes are associated with 
other phenotypic changes (which are discussed below). The natural substrate(s) of PfCRT are yet to be 
identified. Studies performed with other PfCRT expression systems have reported that the protein might 
function as a chloride channel, a proton pump, an activator of Na+/H+ exchangers and non-specific 
cation channels or, most recently, a transporter of cationic amino acids as well as a very broad range of 
other cations15. However, in many of these studies the insertion of PfCRT into the foreign membrane 
required its fusion to other proteins/polypeptides, and in the most recent study the additions to PfCRT 
were at both the N- and C- termini, almost doubled its size, and included a protein of undetermined 
function15. Moreover, in this and the previous studies, little or no interaction could be detected between 
PfCRTDd2 and known inhibitors of this protein (e.g. VP). Of significant note, the transport kinetics for 
the proposed natural substrates did not differ significantly between PfCRTDd2 and PfCRT3D7—despite 
Figure 5. CQ transport activity of the C101F and L272F variants of PfCRT in Xenopus oocytes. (a,b) 
The uptake of [3H]CQ into oocytes expressing PfCRT was measured in the absence (closed bars) or presence 
of 250 μ M VP (light grey bars; a), 100 μ M BSD (dark grey bars; b), or 500 μ M BSD (open bars; b). Within 
each experiment, measurements were made from 10 oocytes per treatment and uptake was expressed 
relative to that measured in the PfCRTDd2-expressing oocytes under control conditions. The normalized 
data obtained from 4–5 separate experiments (each using oocytes from different frogs) were then averaged 
and are shown + SEM. Both panels show PfCRT-mediated CQ uptake, calculated by subtracting CQ uptake 
measured in PfCRT3D7-expressing oocytes (i.e. the component of CQ accumulation attributable to diffusion; 
see Supplementary Fig. S3) from that measured in oocytes expressing a variant of PfCRT. In the control 
treatments, the rates of CQ uptake (pmol/oocyte/h; n = 9 ± SEM) in oocytes expressing PfCRTDd2 and 
PfCRT3D7 were 23.6 ± 2.3 and 1.3 ± 0.2, respectively. ‘ns’ denotes no significant difference (p > 0.05) in CQ 
accumulation between oocytes expressing a PfCRT variant (in the presence or absence of VP or BSD) and 
that measured in the PfCRT3D7-expressing oocytes under control conditions.
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multiple lines of evidence indicating that PfCRTDd2 imparts a substantial fitness cost13,36–38. Furthermore, 
the recent finding that much higher levels of acidic amino acids and/or short acidic peptides accumulate 
within CQ-resistant parasites than in CQ-sensitive strains7,13,14 is not readily reconciled with PfCRT 
functioning as a chloride channel, a proton pump, or a non-specific cation channel/transporter. These, 
plus other inconsistencies in the data, suggest that PfCRT does not function correctly when fused to 
other proteins and that the natural function of PfCRT remains to be resolved.
AMT is an antiviral agent with moderate antimalarial activity that is more potent against CQ-resistant 
parasites than against CQ-sensitive strains39. AMT is likely to accumulate in the FV via weak-base 
trapping40 and is a low-affinity inhibitor of the PfCRTDd2-mediated transport of CQ in the oocyte sys-
tem7. While the antiplasmodial target of AMT remains unclear, AMT resistance has been linked previ-
ously to novel PfCRT mutations (S163R, I356V and V369F; Fig. 1) selected in parasites harboring CQ 
resistance-associated alleles of pfcrt; these mutations were linked with the loss of CQ resistance in the 
AMT-resistant mutants41,42. Here, a different single mutation (C101F) in the CQ-resistant FCB strain was 
likewise associated with a gain of AMT resistance and a reduction in CQ resistance. This mutation was 
identified previously in a PPQ-pressured parasite line that appeared to have acquired an unstable PPQ 
resistance phenotype via multiple genetic changes22. One of two PPQ-revertant lines derived during that 
study was ~2-fold more resistant to PPQ than the parental Dd2 strain, which along with a reduction in 
CQ resistance, is consistent with the data reported here for FCBC101F.
It has been suggested that the S163R mutation reintroduces a positive charge into the PfCRT binding 
pocket/translocation pore, thereby compensating for the loss of the positively-charged lysine residue 
from position 7611 and resulting in a dramatic reduction in the ability of the protein to transport pro-
tonated CQ7. The S163R mutation also abolishes the CQ resistance-reversing effect of VP42. The C101F 
and V369F mutations both entail the introduction of a bulky hydrophobic residue, rather than one car-
rying a positive charge, and it is interesting to note that VP still exerted a resistance-reversing effect in 
the FCBC101F parasites (Table 1)—even though they were considerably less resistant than the FCB strain 
Figure 6. Hypothetical schematic model of the effects of PfCRT mutations. The FV is acidified by 
a vacuolar proton pump to create a suitable environment for hemoglobin digestion. The acidic nature 
of the FV also leads to near complete diprotonation of CQ, which diffuses across the FV membrane 
in an uncharged form (CQ) and accumulates as a charged form (either CQH+ or CQH22+, although 
predominantly CQH22+). CQH22+ interferes with the polymerization of toxic heme to non-toxic hemozoin, 
which leads to parasite death. In normal CQ-sensitive (CQS) parasites, PfCRT, which contains a positive 
charge in its pore (K76), exports its natural substrates but little, if any, CQH22+. Thus, CQH22+ accumulates 
in the FV and causes parasite death. In CQ-resistant (CQR) parasites, the positive change in the pore of 
PfCRT is lost (K76T) and both its natural substrates and CQH22+ are transported out of the FV. As CQH22+ 
cannot accumulate in the FV, the parasites become resistant to the drug. In 3D7L272F parasites (where the 
parent strain is already CQS), the mutation may reduce residual transport of CQH22+ out of the FV even 
further or completely, leading to a greater FV accumulation of CQH22+ and CQ-hypersensitivity or some 
other mechanism may be responsible for this phenomenon. The mutation also leads to a reduction in the 
export of natural substrates, resulting in a build-up of these substrates. This causes water to enter the FV by 
the process of osmosis, leading to swelling. In FCBC101F and Dd2Dd2 L272F parasites (where the parent strains 
are CQR), the mutations reduce the export of CQH22+ back towards levels measured in CQS lines and 
also reduce natural substrate export, leading to normal CQ sensitivity and FV swelling, respectively. Note 
mutations in PfCRT (orange graphic) are denoted by red transmembrane or loop regions, depending on the 
location of the amino acid change (see Fig. 1a).
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to CQ. These observations are consistent with our direct measurements of CQ transport via C101F 
PfCRTDd2 (Fig.  5), which confirmed that this protein possesses a relatively low level of CQ transport 
activity that can be inhibited by VP. Likewise, our finding that the introduction of L272F into PfCRTDd2 
causes a dramatic (but not complete) reduction in the protein’s capacity for CQ transport (Fig. 5) corre-
lates well with the low level of CQ resistance exhibited by the Dd2Dd2 L272F line. The phenylalanine resi-
dues are likely to be proximate to the binding site and/or translocation pore of PfCRT (Fig. 1) where their 
bulky side chains may act to significantly hinder the transport of certain drugs out of the FV, including 
CQ, QN and QD (based on the growth assay data presented in Tables 1 and 2). Another mutation that 
has arisen under the AMT pressure of a CQ-resistant strain, and which also resulted in both the intro-
duction of a phenylalanine residue (V369F) and a significant reduction in CQ resistance, did not cause 
the FV to swell41. Hence, the enlarged FV phenotype described here appears to manifest only when the 
bulky phenylalanine side chain is inserted at specific positions within PfCRT.
BSD is used commercially as a fungicide against a rice blast disease and acts by inhibiting protein 
translation. In biological research it is used to select transformed cells. BSD resistance has previously been 
linked to altered expression of clag3.1 and a decrease in the RBC membrane permeability mediated by the 
new permeability pathways, NPP28,29. Neither 3D7L272F nor Dd2Dd2 L272F parasites differed in their electro-
physiological NPP characteristics when assayed by whole-cell patch-clamp methods (Supplementary Fig. 
S1). This suggests that one or more clag3.1-independent BSD resistance mechanisms exist. Our results 
indicate that, under the conditions of the growth assay, the L272F mutation does not cause a significant 
increase in BSD resistance when introduced in isolation into Dd2 parasites (Table 3). Nevertheless, BSD 
was found to inhibit CQ uptake via PfCRTDd2 and the potency of this interaction appeared to decrease 
upon the introduction of L272F (the addition of 100 μ M BSD was more effective against PfCRTDd2 than 
against L272F PfCRTDd2; Fig.  5). A demonstration that BSD interacts with PfCRTDd2, and to a lesser 
extent with L272F PfCRTDd2, provides support for the idea that BSD also interacts with, and may be 
transported by, PfCRT3D7. BSD contains two protonatable nitrogens with pKa values that are well above 7. 
It is therefore likely to be accumulated within the FV via weak-base trapping to high micromolar, or even 
millimolar, concentrations when present in the extracellular solution at the concentration (5.4 μ M) under 
which the 3D7L272F line arose. Given that BSD inhibits protein translation, which occurs outside of the 
FV, it is possible that a PfCRT3D7-mediated efflux of BSD from the FV could increase the drug’s access to 
its main target and that the L272F mutation diminishes this activity, such that the drug remains seques-
tered within the FV. The finding that L272F PfCRTDd2 does not confer BSD resistance when expressed 
in Dd2 parasites suggests that either (1) PfCRTDd2 is already a poor transporter of BSD (noting that the 
3D7 and Dd2 haplotypes of PfCRT differ by eight mutations) and a reduction in this meager transport 
activity by the introduction of L272F has little effect on the accumulation of BSD within the FV, or (2) 
PfCRTDd2 has a very high capacity for BSD transport, such that the presence of L272F causes only a mod-
est reduction in its ability to redistribute BSD from the FV into the cytosol. In any case, it is clear that if 
L272F is directly involved in altering the parasite’s susceptibility to BSD, its effect is only evident when 
one or more other changes are present. In this regard, it is worth noting that one of the two mutations 
identified by whole genome analysis of the 3D7L272F line would result in a truncated PfMRP2 protein. 
An understanding of the contribution of this transporter to BSD susceptibility, and its possible interplay 
with the BSD transport activity of PfCRT, requires further transfection-based analysis.
A diverse range of PfCRT variants implicated in conferring CQ resistance have been shown to 
exhibit CQ transport activity (to varying extents) in the oocyte system7,32. However, CQ transport via 
the wild-type form of the protein (found in CQ-sensitive parasites such as 3D7) has not been detected 
in this assay. Although it is possible that a very low level of CQ efflux is mediated by PfCRT3D7 in situ, 
and that the introduction of the L272F mutation abolishes this activity, it is perhaps unlikely that this 
would result in the 2-fold difference in the CQ IC50 observed between the 3D7L272F and 3D7 parasites.
An alternative explanation for the hypersensitivity of the 3D7L272F line to CQ and QN entails view-
ing the effect of the L272F mutation as being equivalent to the effect of an ‘anti-PfCRT’ drug. The 
presence of the L272F mutation causes the FV to swell, probably because it significantly obstructs the 
PfCRT-mediated efflux of solutes from this compartment. A drug that binds to the substrate-binding 
site of PfCRT3D7, thereby blocking or dramatically reducing its normal activity, would achieve a similar 
effect. If such an anti-PfCRT drug were applied in combination with CQ or QN, which also exert their 
antimalarial effects in the FV, it is possible that an additive, or even synergistic, interaction would be 
observed in 3D7L272F parasites. That is, the 3D7L272F parasites have a dis-functional FV and this could 
render certain drugs more effective against them; perhaps the altered composition of the FV lumen 
alters the solubilities of CQ and QN and/or their affinities for heme. It is not immediately apparent 
why AQ, MDAQ, and PPQ are not likewise more active against 3D7L272F parasites. However, it is worth 
noting that AQ, MDAQ and PPQ are much more lipophilic than CQ and this may explain differences 
in potency43,44. Hence, the antimalarial activities of the latter drugs might be less sensitive to changes in 
FV volume and composition. Alternatively, or in addition, it is also possible that extending the growth 
assays to 72 or 96 h (from 48 h) would reveal differences in AQ, MDAQ, and PPQ sensitivity between 
the 3D7 and 3D7L272F parasites.
If artemisinins act mainly in the FV, a disputed suggestion45 (along with reports of predominantly 
non-FV-localized artemisinin targets, e.g.46,47), then their activities may also differ between the parental 
and mutant lines. There was no significant change in the ART sensitivity of the 3D7, Dd2 and GC03 lines 
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and only a < 30% change in the IC50 value obtained for FCB (which displays an IC50 value < 15 nM). 
Recent observations made in a P. berghei model using protease knockouts that alter vacuolar morphology 
also leave artemisinin sensitivity unaltered48. This is also consistent with the lack of PfCRT expression 
in early ring stages49, when artemisinins exert their major antimalarial action in vivo. Similarly, the MF 
IC50 value was unaffected in the experiments presented here. Our observations therefore relate relatively 
large changes in the activities of several aminoquinolines to an enlarged FV phenotype that is caused by 
specific mutations in PfCRT.
Our results show for the first time that mutations at position 272 and 101 in PfCRT can hypersensitize 
parasites to CQ and enlarge the FV, thereby extending the function of this key transporter to include 
maintenance of FV morphology. We suggest that the introduction of a phenylalanine residue at either of 
these positions decreases the protein’s ability to transport its physiological substrate(s) (as well as certain 
drugs) and that the resulting build-up of the physiological substrate(s) causes the FV to swell. The fact 
that these mutations do not reintroduce a positive charge into the predicted binding cavity/translocation 
pore of PfCRT, as has been observed in other examples of laboratory parasites that revert to CQ-sensitive 
status (e.g.42), indicates that there is more than one type of single mutation—and therefore more than one 
mechanism—by which the CQ transport activity of PfCRT can be abrogated. This insight extends our 
understanding of the structure-function of PfCRT (e.g.32). Moreover, the finding that single mutations 
to the protein can result in gross changes to parasite morphology emphasizes the central role of this 
transporter in the physiological processes that occur within the FV and provides a novel insight into 
one of the factors constraining the evolution of PfCRT. The observation that BSD binds to, and appears 
to exert a selection pressure on, PfCRT further broadens the diversity of chemotypes that are known (or 
suspected) to interact with the protein. Our data encourage further studies to define agents that could 
reverse antimalarial drug resistance mediated by PfCRT by inhibiting its function.
Methods
Antimalarials and reagents. CQ, QN, QD, MQ, AQ, PPQ, ART, BSD, AMT and VP were purchased 
from Sigma Aldrich Chemical Co. MDAQ was purchased from Santa Cruz Biotechnology, Inc. MDCQ 
was a gift from William Ellis (Walter Reed Army Institute of Research, Silver Spring, MD). SYBR Green 
I was purchased from Invitrogen Corp. Drug stocks were prepared to 10 mM in DMSO or 70% ethanol 
and stored below - 20 °C.
In vitro culture and selection of parasites. P. falciparum 3D7 and 3D7L272F parasites were cul-
tured in human RBC suspensions using RPMI 1640 medium (Sigma-Aldrich; Cat. No. R0883-500ML) 
supplemented with 2 mM L-glutamine, 34 mM HEPES, 0.5% (w/v) Albumax I, 0.19 mM hypoxanthine, 
and 50 μ g/ml gentamycin and maintained at 37 °C under 5% CO2. For parasite clone 3D7L272F, complete 
medium was supplemented with 2.5 μ g/ml blasticidin-S HCl (Invitrogen). Parasite growth was followed 
by microscopic examination of Field’s stained thin blood smears. Synchronization of early trophozoite 
stages was achieved by incubating infected RBCs in 5% (w/v) sorbitol for 10 to 20 min at room temper-
ature50. Following transfection studies23, parasites with abnormally enlarged FVs, as described in results, 
reappeared in culture under BSD pressure after four weeks. In order to select these parasites, the lim-
iting dilution technique was used, and cloned parasites were identified by microscopy using thin blood 
smears51.
P. falciparum FCB and FCBC101F parasites were cultured in AB+ or O+ human RBC suspensions using 
RPMI 1640 medium (Mediatech, Inc.) supplemented with 0.5% Albumax I, 29.8 mM sodium bicarbo-
nate, 25 mM HEPES, 0.37 mM hypoxanthine, and 10 μ g/ml gentamicin and maintained at 37 °C under 
an atmosphere of 90% N2, 5% CO2, and 5% O2. AMT-resistant P. falciparum was selected by single-step 
selection based on an earlier method described for CQ6. Before drug pressure, parasites of the FCB strain 
were grown to 5% mixed stage parasitemia at 5% hematocrit in 50 ml of media. This starter culture was 
then split equally into 4 flasks, with fresh media and RBCs to bring the volume in each flask to 50 ml 
and 5% hematocrit. When parasitemia of the 4 flasks had returned to 5%, the media was replaced with 
fresh media containing 80 μ M AMT. At ~14 fold the IC50 value determined for FCB (Table  2), this 
concentration of AMT rapidly kills CQ-resistant parasites. For the first week after drug application, cul-
tures were monitored daily by Giemsa-stained thin blood films. Fresh AMT-containing media changes 
were performed daily. At one week, 50% of the RBCs were replaced, and fresh AMT media was added. 
Cultures were then maintained every third day with fresh AMT media for the duration of the experiment 
and monitored by thin smear for emergent parasites. With every second media change, 50% of the RBCs 
were replaced with fresh cells. If no surviving parasites were observed after 60 days, the experiment was 
terminated. After 42 days, parasites were recovered from one of the 4 flasks, which were then cloned by 
limiting dilution52 in drug-free media. The mixed culture and four randomly chosen cloned lines were 
cryopreserved prior to DNA sequencing and drug susceptibility testing.
Morphological measurements. For comparison, thin blood films of cultured parasite samples were 
made at various time points following sorbitol synchronization and stained with Field’s stain. Pictures 
were taken under the same conditions for the 3D7 (parent) strain and the 3D7L272F line and analyzed 
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with a Nikon Eclipse TE2000 inverted microscope. Areas were measured using ImageJ 1.44o software 
and the ratio was expressed as AFV/AParasite. No image manipulations were carried out after recording.
For micrographs of FCB and FCBC101F, thin films from parasite cultures were stained with 2% (v/v) 
modified Giemsa (Karyomax® ; Gibco) for 30 min. Slides were washed for 60 s in flowing distilled water, 
air-dried and mounted with coverslips. Images were photographed in bright field, using a Lexica DMI4000 
inverted microscope under a 100X objective lens. Images were compiled in Adobe Photoshop CS5.1 and 
processed equally with a warming photo filter. Live parasite cultures were placed under coverslips and 
photographed under a 100X objective, using a Leica DM750 light microscope equipped with ICC50 HD 
digital camera. Images were adjusted for white balance with the Leica Application Suite software and 
cropped in Adobe Photoshop CS5.1.
For experiments with Dd2 parasites, thin blood smears were fixed with methanol, stained for 20 min 
in 10% (v/v) Giemsa (Invitrogen), washed, and air-dried. Images were taken with an Olympus DP12 
digital camera attached to an Olympus CX 41 light microscope with a 100X objective (N.A 1.4x). Images 
were cropped and corrected for white balance using Adobe Lightroom 3.
Electron microscopy. Samples of 3D7, 3D7L272, Dd2Dd2 and Dd2Dd2 L272F, synchronized at the mature 
trophozoite stage were fixed in 4% (v/v) glutaraldehyde in 0.1 M phosphate buffer and processed for 
routine electron microscopy, as described previously53. Samples were post fixed in osmium tetroxide, 
treated en bloc with uranyl acetate, dehydrated and embedded in Spurr’s epoxy resin. Thin sections were 
stained with uranyl acetate and lead citrate prior to examination in a JEOL1200EX electron microscope.
In vitro inhibition assays. Sensitivity to CQ and other drugs for 3D7 and 3D7L272F parasites was 
determined by measurement of [3H]-hypoxanthine incorporation over 48 h, as described previously54. 
Nine serial dilutions plus a control (no drug) were tested in quadruplicates and the experiment was 
repeated at least three times for each drug. The assay was performed always in parallel on 3D7 and 
3D7L272F parasites.
The in vitro susceptibility of FCB and the FCBC101F line of P. falciparum to antimalarial drugs was 
measured in a 72 h, 96 well microplate fluorescence assay using SYBR Green I detection as described55,56. 
Drugs were serially diluted 2-fold in the microplates, except for AMT, which was diluted 3-fold. VP was 
used at a concentration of 0.8 μ M where indicated. Synchronous (immature) ring-stage parasites were 
assayed at 0.2% parasitemia and 2% hematocrit. Assays were conducted every 48 h until three independ-
ent replicates were performed. For Dd2 parasites, the same methodology was used except parasites were 
also stained with 1.6 μ M Mito Tracker Deep Red.
Genotypic characterization of pfcrt gene. For 3D7 parasites, RNA was extracted from parasites 
collected in RNAlater, using QIAGEN RNeasy Mini Kit, and immediately used to retro-transcribe cDNA 
(QIAGEN, QuantiTect Rev. Transcription Kit). Mutation in pfcrt was investigated by PCR, as described 
previously1. The same primers (Supplementary Table S1), which amplified overlapping products, were 
used to sequence the products to cover the entire open reading frame (ORF) of the gene. Amplification 
of the gene and its sequencing was performed twice (by Beckman Coulter Genomics). Alignment of 
the reported 3D7 gene from PlasmoDB and 3D7 and 3D7L272F sequenced genes was performed using 
MacVector software (version 11.1).
For FCB parasites, 4 clonal lines of FCBC101F were used for pfcrt sequencing. All ORF sequences of 
pfcrt were amplified from P. falciparum genomic DNA57. PCR products were sequenced directly using an 
ABI 3730xl DNA analyzer (Applied Biosystems).
Whole genome sequencing and variant detection. Genomic DNA was isolated and prepared 
from the parental P. falciparum parasite line 3D7 and 3D7L272F. A total of 10 μ g of gDNA from each line 
was sheared to obtain a fragment size of ~200–400 bp using an E220 focused-ultrasonicator (Covaris) 
with the following settings: 10% duty cycle, intensity 5, 200 cycles per burst, 180 s treatment length. 
The resulting sheared gDNA was size selected on a 2% (w/v) low-melting agarose gel and then purified 
and concentrated using MinElute purification columns followed by the QIAquick PCR purification kit 
(QIAGEN). Barcoded libraries for Illumina TruSeq single-end sequencing were then constructed from 
the size-selected, sheared material using NEBNext DNA Library Preparation reagents (New England 
Biolabs) by following the standard Illumina (Illumina) library preparation protocol. Finally, barcoded 
libraries were size selected using Agencourt AMPure XP magnetic beads (Agencourt Biosciences, 
Beckman Coulter) thereby removing any adapter dimers and resulting in a highly enriched barcoded 
library of 200–400 bp adapter-ligated fragments. The quality of the final sequencing libraries was assessed 
using an Agilent 2100 Bioanalyzer (Agilent Technologies) run alongside the original size-selected frag-
mented gDNA from the same preparation, and the concentration of each library was quantified using 
a Quant-iT dsDNA Broad-Range Assay Kit (Invitrogen). The final libraries were multiplexed with three 
barcoded samples and 20% (v/v) PhiX control DNA (Illumina, Catalog # FC-110-3001) per lane and were 
sequenced using an Illumina HiSeq 2500 Rapid Run (150 bp) system (Illumina).
Sequencing outputs were uploaded into Galaxy58, which is hosted locally at the Millennium Science 
Complex at Pennsylvania State University. Sequence reads were mapped to the P. falciparum 3D7 
reference genome v. 10.0 (http://plasmodb.org/common/downloads/release-10.0/Pfalciparum/) and 
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pCam-BSD-PfATP6-doubleHA plasmid sequence23, using the Burrows-Wheeler alignment tool59, and 
files were converted to allow for further analysis (GATK/BAM-to-SAM)60. Sequence variations were 
detected by Freebayes (version 0.9.0.a) using stringent filtering parameters based on quality and read 
depth61,62. Then SNPeff (version 3.3) was applied to annotate and determine statistical significance of 
each variant63. Genome copy number variations were detected based upon local chromosomal read depth 
using CNVnator (version 0.3) and annotated with Intansv (version 0.99.3)64. Alignments and variants 
were visualized using the Integrative Genomics Viewer65. Unique reads were selected and filtered for 
Map Quality > 30.
Plasmid construction and generation of Dd2 recombinant parasites. The donor plasmid pcrtDd2- 
hdhfr has been previously reported31. The mutation-encoding plasmid, pcrtDd2 L272F-hdhfr, was generated 
by site-directed mutagenesis of pcrtDd2-hdhfr, using primers p3527 + p3528 (Supplementary Table S2).
ZFN-editing transfection methods have been previously described31. Briefly, Dd2 parasites were elec-
troporated with either pcrtDd2-hdhfr or pcrtDd2 L272F-hdhfr donor plasmid66. On Day 1 post-electroporation, 
they were cultured in the presence of 2.5 nM WR99210 (obtained from Jacobus Pharmaceuticals Inc.). 
Once recovered, both pcrtDd2-hdhfr and pcrtDd2 L272F-hdhfr transfected parasites were electroporated a 
second time with pZFNcrt-bsd separately. On Day 1 post-electroporation each transfection was cultured 
with 2 μ g/ml blasticidin S (Invitrogen) and 2.5 nM WR99210 for six days and followed by addition of 
only 2.5 nM WR99210, generating Dd2Dd2and Dd2Dd2 L272F parasites, respectively. Clones were established 
from the bulk cultures by limiting dilution52. PCR primers for verification of parental, recombinant con-
trol, and Dd2Dd2 L272F parasite clones are shown in Supplementary Table S2.
Expression of the C101F and L272F variants of PfCRT in X. laevis oocytes and measurements 
of CQ transport. Ethical approval of the work performed with the X. laevis frogs was obtained from 
the Australian National University Animal Experimentation Ethics Committee (Animal Ethics Protocol 
Number A2013/13) in accordance with the Australian Code of Practice for the Care and Use of Animals 
for Scientific Purposes. The C101F PfCRTDd2, L272F PfCRTDd2, and L272F PfCRT3D7 coding sequences 
were generated via site-directed mutagenesis using an approach described previously32. The mutations 
were introduced into codon-harmonized versions of the PfCRTDd2 and PfCRT3D7 coding sequences, 
which encode retention motif-free forms of these proteins that are expressed at the plasma membrane 
of X. laevis oocytes7. All of the resulting coding sequences were verified by sequencing. The in vitro tran-
scription of cRNA and the harvest and preparation of oocytes were performed as outlined elsewhere67. 
The oocytes were microinjected with 20 ng of cRNA and the uptake of [3H]CQ (0.25 μ M; 20 Ci/mmol; 
American Radiolabeled Chemicals) was measured 3–4 days post-injection as detailed previously67. The 
measurements were made over 1.5 h at 27.5 °C and in medium that, unless otherwise specified, con-
tained 96 mM NaCl, 2 mM KCl, 2 mM MgCl2, 1.8 mM CaCl2, 10 mM MES, 10 mM Tris·base (pH 5.5), 
and 15 μ M unlabeled CQ. In all cases, at least three separate experiments were performed (on oocytes 
from different frogs), and in each experiment measurements were made from 10 oocytes per treatment.
Immunofluorescence and western blot analyses of oocytes expressing PfCRT. 
Immunofluorescence analyses were performed on oocytes 3 days post-injection using an approach 
described elsewhere68. Briefly, the oocytes were fixed and labeled with rabbit anti-PfCRT antibody (con-
centration of 1:100; Genscript32; ) and Alexa Fluor 488 goat anti-rabbit antibody (concentration of 1:500; 
Molecular Probes). The oocytes were embedded in an acrylic resin using the Technovit 7100 plastic 
embedding system (Kulzer) as outlined previously69 and images of 4 μ m slices were obtained with a Leica 
Microsystems inverted confocal laser microscope. At least two separate experiments were performed (on 
oocytes from different frogs) for each treatment and slices were examined from a minimum of three 
oocytes within a treatment. All of the slices taken from oocytes expressing a PfCRT variant displayed 
a fluorescent band above the pigment layer (consistent with the localization of PfCRT to the plasma 
membrane) that was not present in non-injected oocytes.
The preparation of oocyte membranes and the semi-quantification of PfCRT protein was carried out 
using a protocol described in detail elsewhere32. Protein samples prepared from oocyte membranes were 
separated on a 4–14% bis-Tris SDS-polyacrylamide gel (Life Technologies) and transferred to nitrocel-
lulose membranes. The membranes were probed with rabbit anti-PfCRT antibody (1:4,000) followed by 
horseradish peroxidase-conjugated goat anti-rabbit antibody (1:8,000; Life Technologies). The PfCRT 
band for each variant was detected by chemiluminescence (Pierce), quantified using the Image J soft-
ware70, and expressed as a percentage of the intensity measured for the PfCRTDd2 band. In all cases, at 
least three separate experiments were performed (on oocytes from different frogs), and in each experi-
ment measurements were averaged from two independent replicates.
Curve fitting and statistical analyses. Mean half-maximal inhibitory concentrations (IC50 val-
ues) were derived by plotting percent growth inhibition against log drug concentration, and fitting the 
response data to a variable slope, sigmoidal curve-fit function for normalized data using Prism 5.0d for 
Macintosh (GraphPad Software). IC50 values represent means ± standard error from 3 independent tests. 
IC50 values between mutant and parent lines were tested for statistically significant differences using an 
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F-test that determines whether the two dose response data sets are best described by single or independ-
ent curve fits (p < 0.05). In the case of the oocyte data, statistical comparisons were made using ANOVA 
in conjunction with Tukey’s multiple comparisons test. Other data were compared using the Student’s 
t-test and Fisher’s exact test as noted.
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